Clinical trial NCT00230581: 8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
Official title: A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Irritable Bowel Syndrome
Keywords: IBS-d, IBS
Lead sponsor: Dynogen Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-10-03
Enrollment: 88
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.

Detailed description: This is a randomized, double-blind, placebo controlled, multicenter study designed to assess the safety and efficacy of DDP225 in patients with IBS-d. Female patients from 18 to 65 years of age with a history of IBS-d for at least 6 months are potentially eligible for entry into the study. A total of 88 eligible patients with IBS-d will be studied.

The total duration of study participation for an individual patient is approximately 10 weeks (74 days) from the initial screening visit to final study evaluations. The total duration of dosing with study medication (either DDP225 or placebo) is 8 weeks.

Patients who satisfy all of the inclusion criteria and none of the exclusion criteria are eligible to enter the Treatment Period and will be randomly assigned to one of four treatment groups.

After a patient is randomized and enters the Treatment Period, she will take the appropriate study medication once a day for 56 days and return to the clinic at two week intervals for a total of four visits during the Treatment Period. During the Treatment Period, patients will maintain a daily diary and complete questionnaires. One week after completing the 56-day Treatment Period, patients return to the clinic for final safety evaluations which include a physical examination, electrocardiogram, and clinical laboratory testing.

Eligibility criteria: Inclusion Criteria:

1. Female patients from 18 to 65 years of age, inclusive.
2. History of IBS-d for at least 6 months prior to the initial screening visit.
3. Endoscopic/radiologic bowel evaluation to rule out cancer, obstruction, or other structural disease.
4. The patient must have completed at least six days of assessments in the patient diary in the one week period prior to the second screening visit.
5. Negative serum and urine pregnancy tests and post-partum for at least one year or not breast feeding at the initial screening visit and throughout the study. For patients able to bear children, an acceptable method of birth control must be used throughout the study. Patients unable to bear children must have documentation of such in the case report form (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]).
6. Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol.

Exclusion Criteria:

1. Serious underlying diseases, including psychiatric disorders or current history of conditions affecting bowel transit including biochemical or structural abnormalities, or GI surgery
2. Clinically significant abnormal examination findings or laboratory tests
3. Inability to stop taking certain medications, or a planned change in medication (including herbal remedies) which could interfere with study assessments
4. Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome
5. Presence of a medical condition which could interfere with the interpretation of study data
6. Significant use of nicotine or caffeine

Primary outcomes:
measure: GI Transit
Secondary outcomes:
measure: Patient Reported Outcomes
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Radiant Research
state: Arizona
city: St. Louis
country: United States
facility: Radiant Research
state: Missouri
city: Great Neck
country: United States
facility: Long Island Gastrointestinal Research
state: New York
city: Mogadore
country: United States
facility: Radiant Research
state: Ohio
city: Greer
country: United States
facility: Radiant Research
state: South Carolina
city: Halifax
country: Canada
facility: QE II Health Sciences Centre
state: Nova Scotia
city: Hamilton
country: Canada
facility: McMaster University Medical Centre
state: Ontario
city: Hamilton
country: Canada
facility: St. Joseph's Healthcare
state: Ontario
city: Kingston
country: Canada
facility: Hotel Dieu Hospital
state: Ontario
city: London
country: Canada
facility: St. Joseph's Healthcare
state: Ontario
city: Ottawa
country: Canada
facility: Meadowlands Family Health Centre
state: Ontario
city: Sarnia
country: Canada
facility: London Road Diagnostic Clinic
state: Ontario
city: Sarnia
country: Canada
facility: Sarnia Institute of Clinical Research
state: Ontario
city: Toronto
country: Canada
facility: Canadian Phase Onward Inc.
state: Ontario
city: Toronto
country: Canada
facility: Toronto Digestive Disease Associates, Inc.
state: Ontario
city: Quebec
country: Canada
facility: Hopital St-Sacrement
Study officials:
affiliation: Hotel Dieu Hospital
name: William Patterson, MD
role: STUDY_CHAIR
References: